Risk of overall medical encounters in patients with type 2 diabetes
(comparison between matched semaglutide vs other anti–diabetes medications groups)

Size/Group	Exposure Group	Comparison Group	Exposure Group Cases (Overall Risk)	Comparison Group Cases(Overall Risk)		HR (95% CI)
17,087	Semaglutide	Insulin	16,894 (98.87%)	16,430 (96.16%)		0.86 (0.85–0.88)
17,080	Semaglutide	Metformin	16,887 (98.87%)	16,571 (97.02%)		1.14 (1.12–1.17)
15,878	Semaglutide	DPP–4i	15,688 (98.80%)	15,334 (96.57%)		1.14 (1.11–1.17)
15,288	Semaglutide	SGLT2i	15,098 (98.76%)	14,839 (97.06%)		1.13 (1.11–1.16)
16,503	Semaglutide	SU	16,312 (98.94%)	15,871 (96.17%)		1.17 (1.14–1.19)
10,847	Semaglutide	TZD	10,682 (98.48%)	10,392 (95.81%)		1.19 (1.16–1.23)
17,029	Semaglutide	Other GLP–1RAs	16,836 (98.87%)	16,601 (97.49%)		1.08 (1.06–1.11)

Hazard Ratio (HR)

0.10 0.20 0.40 0.70 2.0 3.00 5.00 8.00